Purple Biotech (PPBT)

Every figure this model derived for PPBT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2020-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

The ratios

The figures themselves rather than their scores — what somebody looking up PPBT on one particular measure came for.

Everything else this filing tags

231 more elements from PPBT's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.

What to be careful about

What this model itself distrusts about PPBT's figures. Written by the derivation as it ran, not added afterwards.

• operating income last tagged 2025-12-31, -1826 days before the revenue period (2020-12-31); dropped rather than divided by current revenue
• operating cash flow last tagged 2025-12-31, -1826 days before the revenue period (2020-12-31); dropped rather than divided by current revenue
• revenue is annual, not TTM
• revenue period ends 2020-12-31 (2116 days ago) - the tag chain found nothing recent, so treat this row as unscored
• no current stock compensation tagged (last tagged 2025-12-31); treated as zero, so owner earnings are overstated
• no current capital expenditure tagged (last tagged 2025-12-31); treated as zero, so free cash flow is overstated and equals operating cash flow
• the market value here was 2.1B: 1.9B shares from the filing at the quoted price. The price feed reports 1.6M shares, and that count at this same price gives 1.9M, which is the value the feed itself reports. So the two counts are of different things — a depositary receipt against the ordinary shares behind it, or a count filed in thousands — and the count the price belongs to is used
• no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
• analyst estimate not used: no trailing EPS to measure the growth from
• quality DROPPED from the total: only 1 of 5 inputs could be computed (operating margin, roic, owner earnings, cash operating margin not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
• valuation DROPPED from the total: only 0 of 2 inputs could be computed (ev ebit, ev owner earnings not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
• durability rests on 3 of 4 inputs; not tagged: gross margin stability
• resilience DROPPED from the total: only 1 of 3 inputs could be computed (interest cover, liquidity not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
• growth DROPPED from the total: only 1 of 4 inputs could be computed (sustained growth, margin trend, margin recent not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
• 4 of 5 dimensions could not be measured (quality, valuation, resilience, growth -- 90% of the model), so this row is not comparable with the others; its total rests on what was left
• no interest expense tagged while 0M of debt is on the balance sheet, so interest cover is unmeasured rather than perfect